Ikaria has received approval for INOmax from the Therapeutic Goods Administration, Australia.

Ikaria has received approval for INOmax from the Therapeutic Goods Administration, Australia. INOmax is an inhaler which is used in conjunction with ventilatory support and other agents for the treatment of respiratory failure in term and near-term newborns. It is designed for treatment of hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension. INOmax helps critically ill newborns breathe effectively by dilating the blood vessels of the lungs, which in turn helps the oxygen uptake and oxygen supply to the tissues of the body. INOmax supplements the need for the surgical procedure known as extracorporeal membrane oxygenation.

INOmax, in conjunction with ventilatory support and other appropriate agents, is used for the treatment of term and near-term  neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension.